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Walz et al. identify recurrent SIX1, SIX2,
DROSHA, and DGCR8 mutations in pre-
therapy favorable histologyWilms tumors
and find that mutant tumors more often
have blastemal histology. Importantly,
patients whose tumors have SIX1 or SIX2
mutations together with DROSHA or
DGCR8 mutations have poorer survival.
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http://dx.doi.org/10.1016/j.ccell.2015.01.003SUMMARYWe report the most common single-nucleotide substitution/deletion mutations in favorable histology Wilms
tumors (FHWTs) to occur within SIX1/2 (7% of 534 tumors) and microRNA processing genes (miRNAPGs)
DGCR8 and DROSHA (15% of 534 tumors). Comprehensive analysis of 77 FHWTs indicates that tumors
with SIX1/2 and/or miRNAPG mutations show a pre-induction metanephric mesenchyme gene expression
pattern and are significantly associated with both perilobar nephrogenic rests and 11p15 imprinting aberra-
tions. Significantly decreased expression of mature Let-7a and the miR-200 family (responsible for mesen-
chymal-to-epithelial transition) in miRNAPG mutant tumors is associated with an undifferentiated blastemal
histology. The combination of SIX and miRNAPGmutations in the same tumor is associated with evidence of
RAS activation and a higher rate of relapse and death.Significance
We establish recurrence of DGCR8 E518K mutations, confirm the high frequency of recurrent DROSHA exon 29 mutations,
identify recurrent hot spot mutations in the SIX1/2 homeodomain, and identify high frequencies of 11p15 LOI in miRNAPG
and SIX1/2mutant FHWTs. Mutations in miRNAPG were associated with dysregulation of microRNAs involved in oncogen-
esis and mesenchymal-to-epithelial transition and increased frequency of undifferentiated histology. The combination of
multiple genetic events in some FHWTs, including mutations in miRNAPG and SIX1/2 and 11p15 imprinting abnormalities,
provides evidence of a complex, multistep process resulting in failure of normal differentiation, maintenance of progenitor
cells, and support of proliferation. The critical combination of such genetic events is shown to result in an adverse outcome
and may be targetable.
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INTRODUCTION
Wilms tumor (WT) represents the most common pediatric renal
malignancy, with an estimated annual incidence of 500 cases
in the United States (Howlader et al., 2013). WTs commonly
display epithelial, stromal, and undifferentiated (blastemal) com-
ponents in varying proportions and often closely resemble the
different stages of renal development (Rivera and Haber,
2005). They often arise within precursor lesions known as peril-
obar nephrogenic rests (PLNRs) and intralobar nephrogenic
rests (ILNRs) (Beckwith et al., 1990). Evidence suggests that
WT development depends not only on the nature of specific ge-
netic events but also on the timing of their occurrence within
early renal development (Gadd et al., 2012). The developmental
window begins with the early intermediate mesoderm, which
contains progenitor cells of both the urinary collecting system
and pre-induction metanephric mesenchyme. The metanephric
mesenchyme undergoes induction, including mesenchymal-to-
epithelial transition (MET), resulting in nephron development
(Kobayashi et al., 2008).
Mutations inWT1,WTX, and CTNNB1 contribute to WT devel-
opment; in addition, loss of imprinting (LOI) or loss of heterozy-
gosity (LOH) at 11p15 (resulting in biallelic expression of IGF2)
is present in the majority of WTs (Gadd et al., 2012). However,
the identification of 11p15 LOH in normal tissue from some WT
patients (Chao et al., 1993) and the absence of tumor develop-
ment in mutant mice with LOI of 11p15 (Hu et al., 2011) suggest
that biallelic expression of IGF2 alone is insufficient for tumor
development. Five subsets of WT identified on the basis of
gene expression patterns differ in their histology, nephrogenic
rest status, and clinical outcomes and show evidence of arrest
at different stages of renal development (Gadd et al., 2012).
Two subsets express high levels of WT1: subset 1 (5% of
FHWTs) is composed exclusively of epithelial tumors lacking
nephrogenic rests in infants that do not relapse and show a
post-induction metanephric mesenchyme gene expression
pattern; subset 5 (S5;70% of FHWTs) is exemplified by tumors
with 11p15 LOI or LOH that arise within PLNRs and have the
gene expression pattern of pre-induction metanephric mesen-
chyme. The remaining three subsets are defined by a low WT1
expression pattern, are often accompanied by WT1 mutations
and/or deletions, and arise within ILNRs. Subset 2 (S2; 15%
of FHWTs) arises in young infants, shows high expression of
muscle-related genes, has an excellent prognosis, and has a
gene expression pattern of the intermediate mesoderm. Subset
3 (S3; 10% of FHWTs) arises in older children, has a higher
relapse rate, and has a pre-induction metanephric mesenchyme
gene expression pattern without high expression of muscle
genes. Subset 4 (S4; 5% of FHWTs) has a gene expression
profile similar to that of S2 tumors (that of the intermediate
mesoderm) but occurs in older children, and has the highest
relapse rate.
In the United States, WTs are treated with primary resection (if
possible), followed by stage-specific adjuvant chemotherapy,
whereas in Europe, neoadjuvant chemotherapy followed by
resection is the preferred treatment (Dome et al., 2013). More
than 95% of WTs are classified as favorable histology because
they lack evidence of anaplasia (presence of nuclear hyperchro-
masia and enlargement with atypical mitoses, often accompa-Cnied by TP53mutations) (Beckwith and Palmer, 1978; Bardeesy
et al., 1994). Patients with FHWTs, the subject of this study, over-
all have excellent survival (90%); however, more than 15%
relapse, and approximately 40% of these patients eventually
die from their disease (Dome et al., 2002). The National
Cancer Institute’s (NCI) Therapeutically Applicable Research to
Generate Effective Treatments (TARGET) initiative seeks to iden-
tify driver mutations and therapeutic targets for high-risk pediat-
ric tumors through comprehensive integrative genomics (http://
ocg.cancer.gov/programs/target). We report the mutations
commonly identified in FHWTs and place these in their clinical,
pathologic, and developmental contexts.
RESULTS
A discovery set of 77 pre-therapy FHWTs that subsequently
relapsed was analyzed by whole-genome sequencing (WGS;
n = 58) or whole-exome sequencing (WXS; n = 19). Bioinformatic
analysis identified 825 high-quality somatic, non-synonymous
variants, with an average of 11 candidate mutations per case
(range 2–42; Figure S1 available online). Consistent with previous
reports (Ruteshouser et al., 2008), somatic single-nucleotide var-
iants (SNVs) or small deletions were identified inWT1 (three pa-
tients [4%]), in WTX (five patients [6.5%]), and in CTNNB1 (five
patients [6.5%]). Unexpectedly, 12 somatic variants were identi-
fied in microRNA (miRNA) processing genes (miRNAPG) in 11
patients (14%). Last, 8 tumors (10%) had variants in either the
SIX1 or SIX2 homeodomain; strikingly, 5 of 8 SIX1/2 mutant
tumors also had mutations in miRNAPG. None of the miRNAPG
or SIX1/2 variants were annotated as polymorphisms in dbSNP
Versions 134 and 135 (Sherry et al., 2001) or in 1000 Genomes
Pilot Projects 1, 2, and 3 (Abecasis et al., 2012), and none had
been previously identified in COSMIC Version 69 (Forbes et al.,
2011). All variants were verified and expressed by mRNA
sequencing (mRNA-seq). All were predicted to be deleterious
by PolyPhen Version 2 (Adzhubei et al., 2010).
Recurrent SIX1/2 Homeodomain Hot Spot Mutations
In the discovery set, four SIX1 and four SIX2 mutations involved
the same location (p.Q177R) in the SIX homeodomain respon-
sible for DNA binding and protein interaction (Table S1) (Chris-
tensen et al., 2008). Q177 resides in a region conserved in
95%of 100 homologous proteins by a UniProt sequence similar-
ity search (http://www.ncbi.nlm.nih.gov/pubmed/24253303); by
Protein Homology/Analogy Recognition Engine Version 2
(PHYRE2) (Kelley and Sternberg, 2009), this glutamine residue
was predicted to specifically interact with DNA (Figure 1A). All
mutations except one (a tumor with copy neutral LOH for chro-
mosome 2) were heterozygous, with both alleles highly ex-
pressed by mRNA-seq (Figure 1B). In the validation set of 534
FHWTs, the same SIX1 and SIX2 p.Q177R missense mutations
were identified in 23 and 13 patients, respectively, for an overall
frequency of 6.7%. An additional SIX2 variant involved p.Y129N
(Figure 1C; Table S2).
Gene Expression Characteristics of SIX1/2 Q177R
Mutant Tumors
Global gene expression analysis was performed with 75 discov-
ery samples that passed quality control. Unsupervised analysisancer Cell 27, 286–297, February 9, 2015 ª2015 Elsevier Inc. 287
Figure 1. Recurrent SIX1/2 Q177 Mutations in FHWTs
(A) PHYRE2 images showing that the Q177 residue of SIX1 is located within a conserved region (top) and is predicted to be a specific DNA-contact base (bottom;
blue and red indicate regions of low and high likelihood of DNA contact, respectively).
(B) Coverage of the reference allele (blue bar) and variant allele (red bar) as determined by mRNA-seq for SIX1 and SIX2 mutant tumors.
(C) Location of validation set variants within the SIX1 and SIX2 proteins; number of variants detected are provided in parenthesis.
(D) Unsupervised NMF clustering of 75 FHWTs with annotation of mutations identified (bottom; red = somatic, gray = germline).
(E) Supervised hierarchical clustering of 75 FHWTs according to the top 100 genes differentially expressed inSIX1/2mutant tumors with annotation of tumorswith
SIX1/2 mutations and copy number changes (blue = gain, dark red = loss) shown at the bottom.
(F) Boxplots ofMEIS2 and CCND2 in SIX1/2mutants versus wild-type FHWTs. The bottom and top of the box represent the first and third quartiles, respectively;
the band inside the box represents the median; and the whiskers represent the maximum and minimum values.
(G) Boxplots of MEIS2 and CCND2 in NMF cluster 2 SIX1/2 mutants versus wild-type tumors.
See also Figure S1 and Tables S1–S3.
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with non-negative matrix factorization (NMF) (Brunet et al., 2004)
resulted in k = 6 clusters having the highest cophenetic correla-
tion (0.95) after k = 2. NMF cluster 2 contained all seven evalu-
able SIX1/2 mutant tumors (Figure 1D). Gene set enrichment
analysis (GSEA) (Subramanian et al., 2005) comparing the seven
evaluable SIX1/2mutant tumors with all SIX1/2wild-type tumors
identified no significantly enriched canonical pathways, GO bio-
logic processes, or oncogenic signatures. Hierarchical analysis
of the 100 top-ranked differentially expressed genes in the
SIX1/2 mutant tumors by GSEA (Table S3) reveals a similar
distinctive expression pattern for both SIX1- and SIX2-mutant
tumors (Figure 1E), suggesting that they share a common func-
tion. Tumors showing copy number change at the SIX1/2 loci
did not cluster with the mutant tumors, indicating that the muta-
tions may have a neomorph function. The NMF clusters were
then compared with the subsets previously outlined in the Intro-
duction. All tumors in NMF cluster 2 were members of subset 5,
previously characterized by their similarity to the pre-induction
metanephric mesenchyme, including high expression of SIX1,
PAX2, EYA1, SALL1,MEOX1,MEIS2,WASF, andCCND2 (Gadd
et al., 2012) (Figure 1F). To identify genes characterizing SIXmu-
tations within NMF cluster 2, the SIX1/2 mutant tumors were
compared with the SIX1/2 wild-type tumors in this cluster, iden-
tifying 100 top-ranked genes (Table S3), two of which (CCND2
[p = 0.0001] and MEIS2 [p = 0.001]) are illustrated in Figure 1G.
Recurrent miRNAPG Hot Spot Mutations
We identified recurrent somatic mutations in DROSHA (recently
reported [Rakheja et al., 2014; Torrezan et al., 2014]) and
in DGCR8. Last, a somatic variant in XPO5 was identified
(Table S1). The frequency of each mutation was established
within the validation cohort (Figure 2A; Table S2).
DROSHA
In the discovery set, eight somatic DROSHA mutations were
identified in seven patients. Six were missense mutations
involving exon 29 in the ribonuclease (RNase) IIIB domain
responsible for cleaving the 50 end of primary miRNAs to form
precursor miRNAs (Winter et al., 2009), including p.E1147K (4),
p.D1151A (1), and D1151G (1). These residues reside within a
95% conserved region of the protein by UniProt. The two re-
maining variants were nonsense mutations in one patient
(PAKZHF) resulting in loss of both RNase III domains. Therefore,
all mutations affected the RNase IIIB domain of DROSHA.
All DROSHA mutations were heterozygous, and mRNA-seq
confirmed equivalent levels of the mutant and wild-type genes
with the exception of PAKZHF, which had discordant transcript
ratios of 85% (p.Q46*) and 14% (p.R414*) (Figure 2B). These
findings support the reported evidence of a dominant-negative
mechanism for p.E1147 mutations (Rakheja et al., 2014; Wegert
et al., 2015, in this issue of Cancer Cell). Within the validation set
(534 tumors), 59 DROSHA variants were identified in 58 patients
for a frequency of 11%; 42 of 59 variants were either p.E1147 (38)
or p.D1151 (4). Two nonsense variants occurred in one patient.
The remaining 15 were missense with recurrent mutations in
the RNase IIIA domain (p.E969; four tumors) and the RNase
IIIB domain (p.E1222; three tumors).
DGCR8
In the discovery set, 3 p.E518K mutations were identified in the
double-stranded RNA binding domain. E518 is in a regionCconserved in 95%of the 100 top sequences byUniProt. The sec-
ond DGCR8 allele was deleted in all mutant tumors, and mRNA-
seq confirmed an allelic fraction of >90% (Figure 2B). These
observations were likewise reported by Wegert et al. (2015). In
the validation set of 534 tumors, 20 DGCR8 variants (17
p.E518K mutations, a missense variant in exon 12, and 2
nonsense variants in exon 2) resulted in an overall frequency of
4% in FHWTs.
XPO5
One heterozygous somatic nonsense XPO5 mutation was iden-
tified in the discovery set, resulting in loss of the C terminus
required for binding pre-miRNAs (Okada et al., 2009). Within
the validation set, 10 of 534 non-recurring, damaging XPO5 var-
iants spanning the length of the transcript were identified in
seven patients, for a frequency of 1%.
miRNAPG Mutant Tumors Have Reduced Expression of
Critical miRNAs
In the NMF analysis previously described (Figure 1D), cluster 2
contained 8 of 11 tumors with somatic miRNAPG mutations as
well as all SIX1/2 mutant tumors. Clusters 4 and 5 contained
the remaining somatic miRNAPG mutant tumors, one each in
DROSHA p.D1151G, DGCR8 p.E518K, and XPO5. GSEA
comparing miRNAPG mutant tumors (n = 11) with the remainder
(n = 64) revealed significant negative enrichment of three gene
lists, two of which contain genes upregulated in breast cancer
cell cultures overexpressing either MYC-C or E2F3 (Table S4),
suggesting that MYC and E2F3 are relatively inactivated in
miRNAPG mutant tumors compared with other WTs. Hierarchi-
cal analysis using the 100 top-ranked genes differentially ex-
pressed in tumors with miRNAPG somatic mutations by GSEA
(Table S3) shows clustering of all somatic miRNAPG variants
(Figure 2C), supporting a similar underlyingmechanism of action.
Further, tumors showing copy number loss at any of the
miRNAPG loci did not cluster with the mutant tumors unless
they also contained miRNAPG mutations. Intriguingly, DICER1
was expressed at significantly higher levels in tumors with
somatic miRNAPG mutations (p < 0.001; Table S3).
Mutations in miRNAPGs are expected to result in decreased
mature miRNAs and increased primary miRNAs (Winter et al.,
2009); this has recently been documented in 3 mutant and 5
wild-type tumors (Rakheja et al., 2014). To confirm this, we
analyzed mature and primary Let-7a miRNA expression within
77 discovery tumors. Given that haploinsufficient miRNAPGs
may affect function (Lambertz et al., 2010), the samples were
analyzed as three groups: those with somatic miRNAPG muta-
tions (n = 11), those without mutations but with copy number
loss of miRNAPG loci (n = 10), and those without either
miRNAPG somatic mutations or copy number loss (n = 56).
The expression of mature Let-7a was significantly lower in both
tumors with somatic miRNAPG mutations (p = 0.004) and those
with miRNAPG copy number loss (p = 0.047), compared with
those tumors lacking either (Figure 2D; Table S5). Although the
expression of the primary Let-7a transcript (PRI-Let-7a) was
higher in the miRNAPGmutant group compared with those lack-
ing either mutations or copy number loss, this did not achieve
statistical significance.
The effect of miRNAPG mutations on the global miRNA
landscape was evaluated by miRNA sequencing (miRNA-seq).ancer Cell 27, 286–297, February 9, 2015 ª2015 Elsevier Inc. 289
Figure 2. Recurrent miRNAPG Hot Spot Mutations in FHWTs
(A) Location of validation set variants within the DGCR8, DROSHA, XPO5, and DICER1 proteins; numbers of variants detected are provided in parenthesis.
(B) Coverage of the reference allele (blue bar) and variant allele (red bar) as determined by mRNA-seq for DROSHA (top) and DGCR8 (bottom).
(C) Supervised hierarchical clustering of 75 FHWTs according to the top 100 genes differentially expressed in miRNAPG mutant tumors with annotation of
miRNAPG mutations (red = somatic, gray = germline) and copy number loss.
(legend continued on next page)
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Table 1. Significant Validation Set Patient Characteristics
Group Total Number
Age at Diagnosis
(months) Gender (F:M) Blastemal Histology PLNRs ILNRs
DGCR8 E518K variants 17 57 15:2 (p = 0.004) 32/59 (p = 0.003) 27/55 (p < 0.001) 8/55 (p = 0.079)
DROSHA exon 29 variants 42 51 31:11 (p = 0.009)
SIX Q177R variants 36 52 22:14 (not significant) 20/36 (p = 0.008) 16/35 (p = 0.001) 3/35 (p = 0.026)
Entire validation set 534 44 290:244 189 119 125Two-class significance analysis of microarray sequencing
(Tusher et al., 2001) comparing the 11 miRNAPG mutant tumors
with the 56 tumors lacking both mutations and copy number loss
identified 43 differentially expressed miRNAs (false discovery
rate [FDR] < 1% and Benjamini-Hochberg-corrected p < 0.05)
(Table S6). Hierarchical analysis of all 77 tumors using these 43
miRNAs shows localization of 10 of 11 miRNAPGmutant tumors
within a single cluster (cluster 4 in Figure 2E). Tumors with only
SIX1/2 mutations (lacking miRNAPG mutations) and tumors
with copy number loss of themiRNAPG loci without concomitant
miRNAPG mutations did not cluster with the mutant tumors.
Cluster 4 is characterized by decreased expression of the entire
miR-200 family (miR-200a, miR-200b, miR-141, and miR-429)
and miR-181b, all of which are involved in MET and stem cell
maintenance (Hua et al., 2013; Ceppi et al., 2010; Park et al.,
2008; Ceppi and Peter, 2014). Decreased expression of the
miR-200 family is predicted to reduce MYC and E2F expression
(Hua et al., 2013), as was observed in our GSEA of the miRNAPG
mutant tumors.
Correlating SIX1/2 and miRNAPG Mutations with
Clinicopathologic Features
Analysisof thevalidationset revealedasignificant femalepredom-
inance in tumors with DGCR8 E518K and DROSHA exon 29
(miRNAPG-HS) mutations and a greater prevalence of tumors
with blastemal predominant histology in patients with miR-
NAPG-HS and/or SIX1/2 Q177R mutations (Table 1). There was
also a significantly higher association with PLNRs and a lower as-
sociation with ILNRs in those tumors with SIX1/2 Q177R and
miRNAPG-HS mutations (Table 1). Because PLNRs are associ-
ated with loss of the normal imprinting pattern at 11p15 (Ravenel
et al., 2001), 11p15 methylation was analyzed within the 77 dis-
covery set tumors. LOH, LOI, and retention of imprinting (ROI)
were identified in 29 of 77 (38%), 30 of 77 (39%), and 18 of 77
(23%), respectively in the entire group. LOI was significantly
more frequent in both those tumors containing miRNAPG-HS
mutations (seven of nine patients [78%], p = 0.011) and in those
with SIXmutations (seven of eight patients [87.5%], p = 0.003).
Integration of the above clinicopathologic features with muta-
tion, copy number, 11p15 imprinting status, and membership in
gene expression subsets and in miRNA expression categories(D) Mature Let-7a average ddCt (left) and primary Let-7a average ddCt (right) in
lacking both miRNAPG mutations and copy number loss (black bar). Error bars r
(E) Hierarchical analysis of the 43miRNAs significantly differentially expressed in s
mutations and copy number loss, with annotation of miRNAPG mutations and co
respectively. Five clusters were observed, as indicated at the bottom.
See also Tables S4–S6.
Cis provided in Figure 3, arranged by NMF cluster. The NMF
cluster (Figure 3, first row) correlates closely with the previously
reported gene expression subsets (Figure 3, second row, as-
signed as shown in Figure S2) with the exception that S5 is rep-
resented most prominently within two NMF clusters, clusters 1
and 2. NMF cluster 2, which includes the majority of the
miRNAPG mutations and all SIX1/2 mutations, demonstrates
a predominance of tumors in miRNA cluster 4 (defined largely
by low miR-200 family expression), a high prevalence of both
blastemal histology and PLNRs, and a high frequency of
11p15 LOI. The second large S5 predominant group, NMF clus-
ter 1, lacks miRNAPG mutations, does not show reduction of
the miR-200 family, and is associated with ILNRs rather than
PLNRs. This cluster shows a relatively high frequency of
DICER1 loss (through loss of chromosome 14). Loss of one
DICER1 allele results in partial impairment of miRNA process-
ing (Gurtan et al., 2012) and promotes tumorigenesis (Kumar
et al., 2007; Lambertz et al., 2010). These findings suggest
that almost half of the large S5 group may be driven by
miRNAPG and/or SIX mutations, and the possibility remains
that DICER1 loss may contribute to pathogenesis in some of
the remaining S5 tumors.
NMF clusters 3 and 4 contain the majority of the WT1, WTX,
and CTNNB1 mutations; show a high frequency of membership
in S3 and S4 (Figure 3, second row); and are characterized by
mixed histology and an association with ILNRs. The presence
of two tumors in NMF cluster 4 with somatic miRNAPG muta-
tions associated with membership in S4 (characterized by a
gene expression pattern of the intermediate mesoderm and a
high relapse rate) suggests that miRNAPG mutations may also
be pathogenic when they occur earlier in renal development,
within the intermediate mesoderm. The overlap of miRNAPG-
HS and SIX mutations with WT1, WTX, or CTNNB1 mutations
was evaluated in the validation set. Of 36 patients (7%) with
WT1 variants, one DGCR8 E518K and no DROSHA or SIX vari-
ants were present. WTX variants were identified in 31 patients
(6%); in these, one DGCR8 E518K, one DROSHA exon 29, and
three SIX Q177R variants were present. Of 62 patients with
CTNNB1 variants (12%), three DROSHA exon 29 variants, one
SIX Q177R variant, and no DGCR8 variants were also present;
in contrast, 18 also had WT1 variants (a recognized associationFHWTs with miRNAPG mutations (red bar), copy number loss (blue bar), and
epresent +SEM.
omatic miRNAPGmutant FHWTs compared with those lacking bothmiRNAPG
py number loss. Blue and yellow represent relatively high and low expression,
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Figure 3. Integrative Analysis of NMF Clusters
Clinical, pathologic, and genetic features of FHWTs arranged according to the
NMF identified in Figure 1D. The key is illustrated at the bottom. See also
Figure S2.[Maiti et al., 2000]). Of note, we were unable to evaluate exonic
deletions of WT1 and WTX in these data, which represent
70% of the genetic aberrations that occur at these two loci
(Ruteshouser et al., 2008; Gadd et al., 2012).292 Cancer Cell 27, 286–297, February 9, 2015 ª2015 Elsevier Inc.The Combination of SIX1/2 and miRNAPG Mutations
Results in Poor Outcome and RAS Activation
Within the discovery set containing FHWTs that subsequently
relapsed, 5 of 8 tumors (63%) with SIX1/2 mutations also had
somatic miRNAPG-HS mutations. In the validation set of 534 tu-
mors, of 36 tumors with SIX1/2 Q177R variants, 10 (28%) also
had DGCR8 E518K (1) or DROSHA exon 29 (9) variants (p =
0.0015). There was no significant difference in either the rate of
relapse (30%) or the number of deaths (14%) in the entire valida-
tion set compared with patients with DGCR8 E518K or DROSHA
exon 29 variants without SIX Q177R variants (31% and 14%,
respectively) or in those with SIX Q177R variants without
associated miRNAPG-HS variants (31% and 15%, respectively).
However, the 10 patients whose tumors contained both
miRNAPG-HS and SIX Q177R variants had a significantly higher
relapse rate (eight of ten [80%], p = 0.0001; Figure 4) and a higher
rate of death (40%). Hence, although the miRNAPG-HS and SIX
Q177R variants alone do not portend aworse outcome, the com-
bination of these mutations, although rare, appears to result in a
worse outcome.
To identify possible therapeutic targets for this group, we iden-
tified previously published Affymetrix U133A data on 291 of 534
validation tumors and deposited these in the TARGET Data
Matrix (Gadd et al., 2012). GSEA of 22 tumors with miRNAPG-
HS variants and without SIX1/2 variants and the analysis of 12
tumors with SIX1/2 Q177R variants and without miRNAPG-HS
variants did not identify significant enrichment for canonical
pathways, GO biologic processes, or oncogenic signatures,
similar to our experience with the discovery set. In contrast, anal-
ysis of the 6 tumors with available gene expression data with
miRNAPG-HS variants in combination with SIX1/2 Q177R vari-
ants demonstrated a large number of highly significantly
(FDR < 5%) enriched gene lists (Table S4). Although the number
of samples is small, of interest is the positive enrichment of seven
gene sets differentially expressed in a variety of tumor types
following overexpression of an oncogenic KRAS mutation, four
genes sets differentially expressed in a medulloblastoma cell
line following knockdown of PCGF2 (a Polycomb group protein
that functions by transcription repression), and two gene sets
upregulated during embryoid body differentiation.
Germline Variants in miRNAPG Are Identified in FHWTs
Constitutional DICER1 mutations result in development of pleu-
ropulmonary blastoma syndrome (PPBS), which includes cystic
nephroma and, extremely rarely, WT (Doros et al., 2014; Hill
et al., 2009; Slade et al., 2011). Given the recent documentation
of rare DICER1 and DROSHA germline variants in patients with
WT (Rakheja et al., 2014), we examined the discovery set for
germline exonic variants in the miRNAPGs and SIX1/2 and iden-
tified four variants (Figure 2A; Table S1). These were verified with
Sanger sequencing, expressed by mRNA-seq, predicted to be
damaging by PolyPhen Version 2 (Adzhubei et al., 2010), not
annotated as polymorphisms in dbSNP Versions 134 and 135
(Sherry et al., 2001) or present in 1000 Genomes Pilot Projects
1, 2, and 3 (Abecasis et al., 2012). Further, these variants were
not identified in a data set of more than 200,000 individuals
in the National Heart, Lung, and Blood Institute Grand Opportu-
nity Exome Sequencing Project (http://evs.gs.washington.edu/
EVS/). A DROSHA variant (p.P82T) involved the proline-rich
Figure 4. Disease-Free Survival
Kaplan-Meier curve of disease-free survival in the following four
validation set groups: (1) tumors with SIX1/2 and miRNAPG-HS
variants (black line), (2) tumors with miRNAPG-HS variants without
SIX1/2 variants (blue line), (3) SIX1/2 variants without miRNAPG-HS
variants (green line), and (4) all other validation set tumors (red line).domain implicated in protein-protein and protein-nucleic acid in-
teractions (Nicholson, 2014). The remaining allele was retained in
the tumor sample. A germline XPO5 nonsense variant, p.R159*,
located in the exportin-1 domain was identified in the same
patient who had the somatic nonsense XPO5 mutation. Two
missense germline DICER1 variants were identified, one
(p.R1368C) within the RNase IIIA domain and one (p.I85M) in
the helicase ATP-binding domain. Neither of the tumor samples
showed loss of the remaining DICER1 allele. Analysis of the
validation set revealed 9 of 534 damaging DICER1 variants in
eight patients, for an overall frequency of 1.5%. Eight variants
affected the RNase IIIB domain and 6 of 8 were at previously
identified hot spot locations (Doros et al., 2014). Analysis of the
mRNA and miRNA expression patterns of the three germline
mutant tumors that lacked somatic mutations revealed patterns
distinct from that of the somatic miRNAPG mutations (Figures
1D, 2C, 2E, and 3).
DISCUSSION
WT is an embryonal tumor of the kidney remarkable for its repli-
cation of early renal development. Although mutations or dele-
tions in WT1, WTX, and/or CTNNB1 are found in approximately
30%ofWTs (Ruteshouser et al., 2008), the underlying pathogen-
esis of most WTs remains unknown. Hence, in the past few
years, several groups of investigators have simultaneously em-
barked on in-depth molecular characterization studies to further
elucidate the genetic landscape of WTs. Two groups recently re-
ported their findings (Rakheja et al., 2014; Torrezan et al., 2014),
and another group is reporting its findings in this journal (Wegert
et al., 2015). All point to the importance of the DROSHA E1147K
missense mutation in the development of WTs. Torrezan et al.
(2014) evaluated a family trio by WXS, revealing a DROSHA
E1147K mutation and prompting sequencing of the DROSHA
RNase IIIB domain in a validation set of 221 FHWTs (including
amixture of pre- and post-therapy samples frompatients treated
on different protocols). Rakheja et al. (2014) performed WXS inCancer C15 patients followed by validation in 29 tumors, identi-
fying three somatic DROSHA mutations (two E1147K
and one D1151Y). Our study offers the benefits of a
much larger discovery set (77 tumors) and validation
set (534 tumors) composed exclusively of pre-
therapy samples. This allowed the identification of (1)
recurrent somatic mutations inDGCR8 E518K, (2) recur-
rent DROSHA mutations other than E1147K, (3)
recurrent SIX1/2 homeodomain mutations, (4) the asso-
ciation between 11p15 LOI and miRNAPG and SIX mu-
tations, and (5) decreased expression of the miR-200
family in miRNAPG-HS mutant tumors, supporting the
role of MET arrest in the function of these mutations.
Last, the study of a large number of patients treatedon a cooperative group protocol allowed documentation of the
impact of mutations on clinical and pathologic features,
including the association with blastemal histology, nephrogenic
rest status, timing in renal development, the female predomi-
nance in miRNAPG mutant tumors, and the poor clinical
outcome of patients with both miRNAPG-HS and SIX1/2 muta-
tions. The identification of RAS activation in such tumors sug-
gests theymay be treatable in the future with precisionmedicine.
Synthesis of mature miRNA requires normal function of
DGCR8,DROSHA, XPO5, andDICER1. In brief, primary miRNAs
are cleaved in the nucleus by the DROSHA-DGCR8 micropro-
cessor complex to form precursor miRNAs (pre-miRNA), which
are exported from the nucleus by XPO5. Within the cytoplasm,
DICER1 cleaves the pre-miRNA to form mature miRNAs (Winter
et al., 2009). Given the multitude of cellular pathways miRNAs
are known to affect, combined with their interactions and feed-
back loops, the range of effects associated with miRNAPG mu-
tations is likely to be heterogeneous and complex (Hua et al.,
2013). Impaired miRNA synthesis has been shown to accelerate
oncogenic transformation by deregulating target oncogenes and
globally reducing mature miRNA levels (Kumar et al., 2007).
Furthermore, miRNAs have an essential and unique role during
mammalian kidney development (Bartram et al., 2013; Ho and
Kreidberg, 2013). Recent studies have shown that DROSHA
RNase IIIB mutations result in global impairment of miRNA pro-
cessing, with specific impairment in tumor-suppressing miRNAs
(Rakheja et al., 2014). We demonstrate that miRNAPGmutations
are associated with downregulation of all members of the miR-
200 family (miR-200a, miR-200b, miR-200c, miR-141, and
miR-429), which are key regulators of MET (Hua et al., 2013).
Reduction of miR-200 results in a mesenchymal, highly motile,
and aggressive phenotype of cancer cells (Ceppi and Peter,
2014; Park et al., 2008; Ceppi et al., 2010). MET is a critical
step in early renal development during which the capacity to
form nephrons occurs (Kobayashi et al., 2008). Therefore,
decreased expression of these miRNAs in the pre-induction
metanephric mesenchyme would prevent MET, resulting inell 27, 286–297, February 9, 2015 ª2015 Elsevier Inc. 293
failure of epithelial differentiation and a predominance of undif-
ferentiated cells, as was seen in the miRNAPG mutant tumors
we report.
Another miRNA, Let-7a, has long been linked to tumor devel-
opment (reviewed in Garzon et al. [2009]), and decreased Let-7a
expression has been implicated in the development of WT via
upregulation of LIN28 (Urbach et al., 2014). LIN28 is a RNA-bind-
ing protein that specifically binds to PRI/PRE-Let-7 miRNAs,
preventing maturation (Viswanathan et al., 2009). In the murine
embryonic kidney, overexpression of LIN28within the pre-induc-
tion metanephric mesenchyme results in sustained proliferation,
failure of MET, and tumor formation, a process that is rescued by
Let-7 overexpression (Urbach et al., 2014). Of particular interest,
overexpression of LIN28 in the post-induction metanephric
mesenchyme failed to result in tumor development, suggesting
that the effects of miRNAPG mutations depend on the cellular
context in which they arise. Rakheja et al. (2014) functionally
confirmed that DROSHA E1147K and D1151Y mutations result
in decreased expression of the Let-7 family within an in vitro
model; in this study, we now confirm decreased Let-7a in a large
population of miRNAPG mutant WTs.
Non-recurrent germline variants were also identified in
miRNAPG, although these tumors were outliers by gene expres-
sion and miRNA expression compared with those containing so-
matic mutations. Therefore, germline miRNAPG variants do not
appear to function in the samemanner as the somatic miRNAPG
mutations, and there is no direct evidence that they are patho-
genic. Germline DICER1 variants constitute the greatest clinical
concern because of their association with familial PPBS. How-
ever, available data suggest that this syndrome follows a
classic two-hit model of tumorigenesis, with germline truncating
DICER1 mutations followed by deleterious somatic missense
mutations involving the RNase IIIB domain (Doros et al., 2014).
Both germline and somatic DICER1 mutations were observed
in three WTs by Wu et al. (2013) and in one WT by Rakheja
et al. (2014), who also described an additional patient with a
germline DICER1 mutation only, similar to our two discovery
cases. The contribution of germline DICER1 variants (as well
as germline DROSHA and XPO5 variants) in such patients is
not clear. However, their repeated identification in patients with
WT suggests that they may result in a predisposition to WT;
our study documents this risk to be present in approximately
1.3% of FHWTs.
Recurrent mutations involving a specific residue of the home-
odomain of transcription factors SIX1 and SIX2were identified in
7% of FHWTs. The highly homologous SIX1 and SIX2 genes
have a critical role in renal development (Christensen et al.,
2008; Xu et al., 2003). SIX1-deficient mice exhibit renal hypopla-
sia or agenesis (Li et al., 2003), and SIX1mutations have been re-
ported in the branchio-oto-renal (BOR) syndrome, although at
positions distant from Q177R; BOR syndrome is not associated
with WT (Patrick et al., 2009). SIX2maintains a population of un-
differentiated renal blastemal cells, and loss of SIX2 results in
premature differentiation of mesenchymal cells into epithelia
(Kobayashi et al., 2008; Self et al., 2006). Within a renal cell
line, overexpression of SIX2 results in an increased percentage
of cells in the S phase and increased migration (Senanayake
et al., 2013). Given the known function of SIX1 and SIX2, the
localization of mutations within the SIX homeodomain, and the294 Cancer Cell 27, 286–297, February 9, 2015 ª2015 Elsevier Inc.high expression of both mutant and wild-type alleles, it is
probable that these SIX1/2 mutations in FHWTs are activating,
resulting in failure of MET and continued proliferation of the
metanephric mesenchyme. Indeed, we demonstrate significant
upregulation of CCND2 in SIX mutant tumors, which may be
an important underlying cause of the continued proliferation.
These findings are supported by those of Wegert et al. (2015),
who report increased expression of both cell cycle genes and
genes highly expressed in the pre-induction metanephric
mesenchyme.
In summary, mutations in miRNAPG and/or SIX1/2 genes are
identified in approximately 20% of FHWTs. Clinical, pathologic,
gene, and miRNA expression data support disruption of MET
at the time of induction as the underlying mechanism of tumori-
genesis in this group of WTs, although no direct functional data
are presented to confirm this hypothesis. Lastly, the very high
prevalence of 11p15 LOI in WTs harboring both miRNAPG-HS
andSIXQ177Rmutations provides further evidence thatmultiple
genetic events may be involved in the development and progres-
sion of WTs.
EXPERIMENTAL PROCEDURES
The TARGET initiative maintains public availability of the gene expression,
chromosome copy number, DNA methylation, sequence analysis (i.e., muta-
tion annotation format and summary files), and clinical information for the
cases studied (available through the TARGET Data Matrix; http://target.nci.
nih.gov/dataMatrix/TARGET_DataMatrix.html) in fully annotated Minimum In-
formation About a Microarray Experiment-compliant microarray gene expres-
sion - tabular files describing the methods, specimen processing details, and
quality control parameters. The aligned sequencing data (binary sequence
alignment data [BAM] files) are deposited in the Sequence Read Archive at
the National Center for Biotechnology Information and are accessible through
the database of Genotypes and Phenotypes (http://www.ncbi.nlm.nih.gov/
gap) under the accession number phs000471. See Supplemental Experi-
mental Procedures for details.
Specimens
Pre-therapy tumor and normal DNA from peripheral blood or kidney from 77
FHWTs banked by the Children’s Oncology Group (COG) with parental
informed consent were included in the discovery set. A validation set of pa-
tients registered on the National Wilms Tumor Study-5 protocol included all
patients with available primary tumor DNA who subsequently relapsed and a
random selection of all patients irrespective of relapse, resulting in 534 tumors
enriched for relapse. Studies were performed with the approval of the Lurie
Children’s Hospital Institutional Review Board.
DNA Sequencing
WGS libraries were sequenced using Complete Genomics (CGI) technology
(Drmanac et al., 2010); alignment of reads to the National Center for Biotech-
nology Information Build 37 reference human genome assembly was per-
formed by the CGI Cancer Sequencing service analytic pipeline Version 2
(Carnevali et al., 2012). WXS was performed on the Illumina HiSeq platform.
Variant calling from the aligned BAM files was performed using both ATLAS
and SAMtools, and annotation and filtering were performed using the SACBE
annotation pipeline (Bainbridge et al., 2013; Lupski et al., 2013) as well as
Bambino Version 1.05 (Edmonson et al., 2011).
mRNA-Seq and miRNA-Seq
Libraries were prepared following a paired-end protocol and sequenced on the
Illumina HiSeq 2000/2500 platform using HiSeq Control Software Version
2.0.10, aligned to GRCh37-lite genome-plus-junctions reference (Morin
et al., 2008) using BWAVersion 0.5.7 (Li and Durbin, 2009). FormRNA analysis,
variants were detected on positive- and negative-split BAMs separately and
annotated with SnpEff (Cingolani et al., 2012a) (Ensembl 66) and SnpSift (Cin-
golani et al., 2012b) (dbSNP137 and COSMIC64). For miRNA analysis, reads
aligning to known miRNAs in miRBase v20 were summed and normalized to
1 million miRNA-aligned reads to generate the quantification files.
Target Capture Sequence Analysis
Probes were designed using Agilent’s SureDesign (https://earray.chem.
agilent.com/suredesign/), and probe density was specified at 23 with
98.7144% coverage of the target region (Agilent SureSelect XT Custom 0.5-
2.9Mb probes). Genomic DNA libraries were constructed as described above
and hybridized to the RNA probes. Post-capture material was enriched with
ten cycles of PCR. Paired-end 100-base readswere sequenced on the Illumina
HiSeq2500 instrument. SNVs were filtered out if not predicted to be damaging
by at least two-thirds of the following: SIFT (McLaren et al., 2010), PolyPhen
Version 2 (Adzhubei et al., 2010), or Provean Version 1.1.3 (Choi et al., 2012).
Copy number analysis was performed on tumor and normal pairs according
to the manufacturer’s protocol for the AffyMetrix 6.0 SNP array and processed
using AffyMetrix Genotyping Console 4.0 software. Reference normalization
utilizing a diploid chromosome for each sample (Pounds et al., 2009) was per-
formed in R using the DNAcopy BioConductor package. Segmented regions
were identified by circular binary segmentation, and those containing at least
eight markers in which the log2 value wasR +0.5 or% 0.5 were considered
gained or lost, respectively.
Gene expression analysis was performed with the Affymetrix U133+2 chip,
according to themanufacturer’s protocol using the Gene-Chip Operating Soft-
ware and normalized using robust multichip average normalization. Unsuper-
vised analysis was performed using Non-negative Matrix Factorization
Consensus Version 5 (Brunet et al., 2004). GSEA Version 2.0.14 (http://www.
broadinstitute.org/gsea) (Subramanian et al., 2005) was run using 1,000 per-
mutations and phenotype permutation. Significant enrichment was defined
as those lists with >50 genes, an FDR < 10%, and a p value < 5%.
Methylation analysis was performed with Illumina Infinium Human Methyl-
ation 450K Bead Chips, according to the manufacturer’s protocol. Methylation
levels for all probes in imprint control regions ICR1 (IGF2/H19) and ICR2
(KCNO1/CDKN1C) were averaged. ROI was defined as 0.3 to 0.7 for ICR1
and ICR2, LOI as 0.8 to 1 for ICR1 and 0.3 to 0.7 for ICR2, and LOH as 0.8
to 1 for ICR1 and 0 to 0.2 for ICR2. Tumors outside of these ranges were not
classified.
Let-7a Mature and Primary miRNA Expression
Reverse transcription, amplification, and real-time PCR were performed per
the manufacturer’s protocol (Life Technologies). Samples were run in triplicate
and analyzed using the Applied Biosystems 7500 Fast SDS Software (Life
Technologies). Nuclear and cytoplasmic fractions from HEK293 cells (ATCC)
were evaluated for mature and primary Let-7a expression to confirm probe
specificity.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
two figures, and six tables and can be found with this article online at http://
dx.doi.org/10.1016/j.ccell.2015.01.003.
AUTHOR CONTRIBUTIONS
A.L.W. and A.O. performed the miRNAPG and SIX1/2 mutation analyses,
respectively; both contributed equally to the writing of the manuscript.
D.S.G., J.M.G.A., and M.A.S. oversaw the administrative and data manage-
ment of the TARGET project. D.M., C.H.H., C.Y., C.N., Q.-R.C., and Y.H. pro-
vided the bioinformatic analysis for WXS and copy number and methylation-
expression correlation. Y.-Y.C. provided the statistical analysis. J.M.G.-F.
and N.R. performed the specimen processing and quality control. J.S.D. and
V.H. provided the samples and the clinical data. C.G.M. and J.M. performed
the copy number analysis. S.G. performed the gene expression analysis and
bioinformatics for gene expression, miRNA expression, and protein analysis.
Y.M., A.J.M., R.A.M., J.S., D.B., R.B., and M.A.M. performed the mRNA-
seq, miRNA-seq, and target capture sequencing. D.A.W. and O.A.H. per-
formed the WXS. N.J. performed the methylation analysis. E.J.P. designedCand oversaw all aspects of the study. All authors contributed to the
manuscript.
ACKNOWLEDGMENTS
The TARGET initiative is supported by NCI Grant U10 CA98543. Work per-
formed under contracts from the NCI, National Institutes of Health (NIH), within
HHSN261200800001E includes specimen processing (the COG Biopathology
Center), WGS (CGI), WXS (Baylor College of Medicine), miRNA-seq, RNA
sequencing, and target capture sequencing (British Columbia Cancer Agency
Genome Sciences Center). The content of this publication does not neces-
sarily reflect the views or policies of the Department of Health and Human Ser-
vices, nor does the mention of trade names, commercial products, or organi-
zations imply endorsement by the USA government. We thank Patee Gesuwan
and Leandro Hermida and the Data Coordinating Center for their support. We
also thank the Clinical Applications of Core Technology Laboratory of the Hart-
well Center for Bioinformatics and Biotechnology of St. Jude Children’s
Research Hospital for performing the copy number analysis and the North-
western University Genomic Core facility for performing the methylation anal-
ysis. This work is also supported by NCI T32 CA079447 (A.L.W.), NIH
U10CA42326 (E.J.P.), U10CA98543 (J.S.D., E.J.P.), U24 CA114766,
UO1CA88131 (E.J.P.), and the American and Lebanese Syrian Associated
Charities of St. Jude (J.M., C.G.M.). We are grateful for the expertise of Karen
Novik and Laura Monovich, Patricia Beezhold, Donna Kersey, Debbie-Payne
Turner, Mary McNulty, and Yvonne Moyer. This work would not be possible
without the dedication of all the experts within the many clinical disciplines
at the local institutions and centrally within the COG and the National Wilms
Tumor Study Group.
Received: August 28, 2014
Revised: November 28, 2014
Accepted: January 12, 2015
Published: February 9, 2015
REFERENCES
Abecasis, G.R., Auton, A., Brooks, L.D., DePristo, M.A., Durbin, R.M.,
Handsaker, R.E., Kang, H.M., Marth, G.T., and McVean, G.A.; 1000
Genomes Project Consortium (2012). An integrated map of genetic variation
from 1,092 human genomes. Nature 491, 56–65.
Adzhubei, I.A., Schmidt, S., Peshkin, L., Ramensky, V.E., Gerasimova, A.,
Bork, P., Kondrashov, A.S., and Sunyaev, S.R. (2010). A method and server
for predicting damaging missense mutations. Nat. Methods 7, 248–249.
Bainbridge, M.N., Hu, H., Muzny, D.M., Musante, L., Lupski, J.R., Graham,
B.H., Chen, W., Gripp, K.W., Jenny, K., Wienker, T.F., et al. (2013). De novo
truncating mutations in ASXL3 are associated with a novel clinical phenotype
with similarities to Bohring-Opitz syndrome. Genome Med 5, 11.
Bardeesy, N., Falkoff, D., Petruzzi, M.J., Nowak, N., Zabel, B., Adam, M.,
Aguiar, M.C., Grundy, P., Shows, T., and Pelletier, J. (1994). Anaplastic
Wilms’ tumour, a subtype displaying poor prognosis, harbours p53 gene mu-
tations. Nat. Genet. 7, 91–97.
Bartram, M.P., Ho¨hne, M., Dafinger, C., Vo¨lker, L.A., Albersmeyer, M., Heiss,
J., Go¨bel, H., Bro¨nneke, H., Burst, V., Liebau, M.C., et al. (2013). Conditional
loss of kidneymicroRNAs results in congenital anomalies of the kidney and uri-
nary tract (CAKUT). J. Mol. Med. 91, 739–748.
Beckwith, J.B., and Palmer, N.F. (1978). Histopathology and prognosis of
Wilms tumors: results from the First National Wilms’ Tumor Study. Cancer
41, 1937–1948.
Beckwith, J.B., Kiviat, N.B., and Bonadio, J.F. (1990). Nephrogenic rests,
nephroblastomatosis, and the pathogenesis of Wilms’ tumor. Pediatr.
Pathol. 10, 1–36.
Brunet, J.P., Tamayo, P., Golub, T.R., and Mesirov, J.P. (2004). Metagenes
and molecular pattern discovery using matrix factorization. Proc. Natl. Acad.
Sci. U S A 101, 4164–4169.
Carnevali, P., Baccash, J., Halpern, A.L., Nazarenko, I., Nilsen, G.B., Pant,
K.P., Ebert, J.C., Brownley, A., Morenzoni, M., Karpinchyk, V., et al. (2012).ancer Cell 27, 286–297, February 9, 2015 ª2015 Elsevier Inc. 295
Computational techniques for human genome resequencing usingmated gap-
ped reads. J. Comput. Biol. 19, 279–292.
Ceppi, P., and Peter, M.E. (2014). MicroRNAs regulate both epithelial-to-
mesenchymal transition and cancer stem cells. Oncogene 33, 269–278.
Ceppi, P., Mudduluru, G., Kumarswamy, R., Rapa, I., Scagliotti, G.V., Papotti,
M., and Allgayer, H. (2010). Loss of miR-200c expression induces an aggres-
sive, invasive, and chemoresistant phenotype in non-small cell lung cancer.
Mol. Cancer Res. 8, 1207–1216.
Chao, L.Y., Huff, V., Tomlinson, G., Riccardi, V.M., Strong, L.C., and Saunders,
G.F. (1993). Genetic mosaicism in normal tissues of Wilms’ tumour patients.
Nat. Genet. 3, 127–131.
Choi, Y., Sims, G.E., Murphy, S., Miller, J.R., and Chan, A.P. (2012). Predicting
the functional effect of amino acid substitutions and indels. PLoS ONE 7,
e46688.
Christensen, K.L., Patrick, A.N., McCoy, E.L., and Ford, H.L. (2008). The six
family of homeobox genes in development and cancer. Adv. Cancer Res.
101, 93–126.
Cingolani, P., Platts, A., Wang, L., Coon, M., Nguyen, T., Wang, L., Land, S.J.,
Lu, X., and Ruden, D.M. (2012a). A program for annotating and predicting the
effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of
Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 6, 80–92.
Cingolani, P., Patel, V.M., Coon, M., Nguyen, T., Land, S.J., Ruden, D.M., and
Lu, X. (2012b). Using Drosophila melanogaster as amodel for genotoxic chem-
ical mutational studies with a new program, SnpSift. Front. Genet. 3, 35.
Dome, J.S., Liu, T., Krasin, M., Lott, L., Shearer, P., Daw, N.C., Billups, C.A.,
and Wilimas, J.A. (2002). Improved survival for patients with recurrent Wilms
tumor: the experience at St. Jude Children’s Research Hospital. J. Pediatr.
Hematol. Oncol. 24, 192–198.
Dome, J.S., Fernandez, C.V., Mullen, E.A., Kalapurakal, J.A., Geller, J.I., Huff,
V., Gratias, E.J., Dix, D.B., Ehrlich, P.F., Khanna, G., et al.; COG Renal Tumors
Committee (2013). Children’s Oncology Group’s 2013 blueprint for research:
renal tumors. Pediatr. Blood Cancer 60, 994–1000.
Doros, L.A., Rossi, C.T., Yang, J., Field, A., Williams, G.M., Messinger, Y.,
Cajaiba, M.M., Perlman, E.J., A Schultz, K., Cathro, H.P., et al. (2014).
DICER1 mutations in childhood cystic nephroma and its relationship to
DICER1-renal sarcoma. Mod. Pathol. 27, 1267–1280.
Drmanac, R., Sparks, A.B., Callow, M.J., Halpern, A.L., Burns, N.L., Kermani,
B.G., Carnevali, P., Nazarenko, I., Nilsen, G.B., Yeung, G., et al. (2010). Human
genome sequencing using unchained base reads on self-assembling DNA
nanoarrays. Science 327, 78–81.
Edmonson, M.N., Zhang, J., Yan, C., Finney, R.P., Meerzaman, D.M., and
Buetow, K.H. (2011). Bambino: a variant detector and alignment viewer for
next-generation sequencing data in the SAM/BAM format. Bioinformatics
27, 865–866.
Forbes, S.A., Bindal, N., Bamford, S., Cole, C., Kok, C.Y., Beare, D., Jia, M.,
Shepherd, R., Leung, K., Menzies, A., et al. (2011). COSMIC: mining complete
cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic
Acids Res. 39, D945–D950.
Gadd, S., Huff, V., Huang, C.C., Ruteshouser, E.C., Dome, J.S., Grundy, P.E.,
Breslow, N., Jennings, L., Green, D.M., Beckwith, J.B., and Perlman, E.J.
(2012). Clinically relevant subsets identified by gene expression patterns sup-
port a revised ontogenic model of Wilms tumor: a Children’s Oncology Group
Study. Neoplasia 14, 742–756.
Garzon, R., Calin, G.A., and Croce, C.M. (2009). MicroRNAs in Cancer. Annu.
Rev. Med. 60, 167–179.
Gurtan, A.M., Lu, V., Bhutkar, A., and Sharp, P.A. (2012). In vivo structure-func-
tion analysis of human Dicer reveals directional processing of precursor
miRNAs. RNA 18, 1116–1122.
Hill, D.A., Ivanovich, J., Priest, J.R., Gurnett, C.A., Dehner, L.P., Desruisseau,
D., Jarzembowski, J.A., Wikenheiser-Brokamp, K.A., Suarez, B.K., Whelan,
A.J., et al. (2009). DICER1 mutations in familial pleuropulmonary blastoma.
Science 325, 965.
Ho, J., and Kreidberg, J.A. (2013). MicroRNAs in renal development. Pediatr.
Nephrol. 28, 219–225.296 Cancer Cell 27, 286–297, February 9, 2015 ª2015 Elsevier Inc.Howlader, N., Noone, A.M., Krapcho, M., Garshell, J., Neyman, N., Altekruse,
S.F., Kosary, C.L., Yu, M., Ruhl, J., Tatalovich, Z., et al. (2013). SEER Cancer
Statistics Review, 1975-2010. (Bethesda: National Cancer Institute). http://
seer.cancer.gov/csr/1975_2010/.
Hu, Q., Gao, F., Tian, W., Ruteshouser, E.C., Wang, Y., Lazar, A., Stewart, J.,
Strong, L.C., Behringer, R.R., and Huff, V. (2011). Wt1 ablation and Igf2 upre-
gulation in mice result in Wilms tumors with elevated ERK1/2 phosphorylation.
J. Clin. Invest. 121, 174–183.
Hua, Y., Larsen, N., Kalyana-Sundaram, S., Kjems, J., Chinnaiyan, A.M., and
Peter, M.E. (2013). miRConnect 2.0: identification of oncogenic, antagonistic
miRNA families in three human cancers. BCM Genom. 14, 179, (http://www.
biomedcentral.com/1471-2164/14/179).
Kelley, L.A., and Sternberg, M.J. (2009). Protein structure prediction on the
Web: a case study using the Phyre server. Nat. Protoc. 4, 363–371.
Kobayashi, A., Valerius, M.T., Mugford, J.W., Carroll, T.J., Self, M., Oliver, G.,
and McMahon, A.P. (2008). Six2 defines and regulates a multipotent self-
renewing nephron progenitor population throughout mammalian kidney devel-
opment. Cell Stem Cell 3, 169–181.
Kumar, M.S., Lu, J., Mercer, K.L., Golub, T.R., and Jacks, T. (2007). Impaired
microRNA processing enhances cellular transformation and tumorigenesis.
Nat. Genet. 39, 673–677.
Lambertz, I., Nittner, D., Mestdagh, P., Denecker, G., Vandesompele, J., Dyer,
M.A., and Marine, J.C. (2010). Monoallelic but not biallelic loss of Dicer1 pro-
motes tumorigenesis in vivo. Cell Death Differ. 17, 633–641.
Li, H., and Durbin, R. (2009). Fast and accurate short read alignment with
Burrows-Wheeler transform. Bioinformatics 25, 1754–1760.
Li, X., Oghi, K.A., Zhang, J., Krones, A., Bush, K.T., Glass, C.K., Nigam, S.K.,
Aggarwal, A.K., Maas, R., Rose, D.W., and Rosenfeld, M.G. (2003). Eya protein
phosphatase activity regulates Six1-Dach-Eya transcriptional effects in
mammalian organogenesis. Nature 426, 247–254.
Lupski, J.R., Gonzaga-Jauregui, C., Yang, Y., Bainbridge, M.N., Jhangiani, S.,
Buhay, C.J., Kovar, C.L., Wang, M., Hawes, A.C., Reid, J.G., et al. (2013).
Exome sequencing resolves apparent incidental findings and reveals further
complexity of SH3TC2 variant alleles causing Charcot-Marie-Tooth neuropa-
thy. Genome Med. 5, 57–70.
Maiti, S., Alam, R., Amos, C.I., and Huff, V. (2000). Frequent association of
b-catenin and WT1 mutations in Wilms tumors. Cancer Res. 60, 6288–6292.
McLaren, W., Pritchard, B., Rios, D., Chen, Y., Flicek, P., and Cunningham, F.
(2010). Deriving the consequences of genomic variants with the Ensembl API
and SNP Effect Predictor. Bioinformatics 26, 2069–2070.
Morin, R., Bainbridge, M., Fejes, A., Hirst, M., Krzywinski, M., Pugh, T.,
McDonald, H., Varhol, R., Jones, S., and Marra, M. (2008). Profiling the HeLa
S3 transcriptome using randomly primed cDNA and massively parallel short-
read sequencing. Biotechniques 45, 81–94.
Nicholson, A.W. (2014). Ribonuclease III mechanisms of double-stranded RNA
cleavage. Wiley Interdiscip. Rev. RNA 5, 31–48.
Okada, C., Yamashita, E., Lee, S.J., Shibata, S., Katahira, J., Nakagawa, A.,
Yoneda, Y., and Tsukihara, T. (2009). A high-resolution structure of the pre-
microRNA nuclear export machinery. Science 326, 1275–1279.
Park, S.M., Gaur, A.B., Lengyel, E., and Peter, M.E. (2008). ThemiR-200 family
determines the epithelial phenotype of cancer cells by targeting the E-cadherin
repressors, ZEB1 and ZEB2. Genes Dev. 22, 894–907.
Patrick, A.N., Schiemann, B.J., Yang, K., Zhao, R., and Ford, H.L. (2009).
Biochemical and functional characterization of six SIX1 branchio-oto-renal
syndrome mutations. J. Biol. Chem. 284, 20781–20790.
Pounds, S., Cheng, C., Mullighan, C., Raimondi, S.C., Shurtleff, S., and
Downing, J.R. (2009). Reference alignment of SNP microarray signals for
copy number analysis of tumors. Bioinformatics 25, 315–321.
Rakheja, D., Chen, K.S., Liu, Y., Shukla, A.A., Schmid, V., Chang, T.C.,
Khokhar, S., Wickiser, J.E., Karandikar, N.J., Malter, J.S., et al. (2014).
Somatic mutations in DROSHA and DICER1 impair microRNA biogenesis
through distinct mechanisms in Wilms tumours. Nat. Commun. 2, 4802.
Ravenel, J.D., Broman, K.W., Perlman, E.J., Niemitz, E.L., Jayawardena, T.M.,
Bell, D.W., Haber, D.A., Uejima, H., and Feinberg, A.P. (2001). Loss of
imprinting of insulin-like growth factor-II (IGF2) gene in distinguishing specific
biologic subtypes of Wilms tumor. J. Natl. Cancer Inst. 93, 1698–1703.
Rivera, M.N., and Haber, D.A. (2005). Wilms’ tumour: connecting tumorigen-
esis and organ development in the kidney. Nat. Rev. Cancer 5, 699–712.
Ruteshouser, E.C., Robinson, S.M., and Huff, V. (2008). Wilms tumor genetics:
mutations in WT1,WTX, and CTNNB1 account for only about one-third of tu-
mors. Genes Chromosomes Cancer 47, 461–470.
Self, M., Lagutin, O.V., Bowling, B., Hendrix, J., Cai, Y., Dressler, G.R., and
Oliver, G. (2006). Six2 is required for suppression of nephrogenesis and pro-
genitor renewal in the developing kidney. EMBO J. 25, 5214–5228.
Senanayake, U., Koller, K., Pichler, M., Leuschner, I., Strohmaier, H., Hadler,
U., Das, S., Hoefler, G., and Guertl, B. (2013). The pluripotent renal stem cell
regulator SIX2 is activated in renal neoplasms and influences cellular prolifer-
ation and migration. Hum. Pathol. 44, 336–345.
Sherry, S.T., Ward, M.H., Kholodov, M., Baker, J., Phan, L., Smigielski, E.M.,
and Sirotkin, K. (2001). dbSNP: the NCBI database of genetic variation.
Nucleic Acids Res. 29, 308–311.
Slade, I., Bacchelli, C., Davies, H., Murray, A., Abbaszadeh, F., Hanks, S.,
Barfoot, R., Burke, A., Chisholm, J., Hewitt, M., et al. (2011). DICER1 syn-
drome: clarifying the diagnosis, clinical features andmanagement implications
of a pleiotropic tumour predisposition syndrome. J. Med. Genet. 48, 273–278.
Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L.,
Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., and
Mesirov, J.P. (2005). Gene set enrichment analysis: a knowledge-based
approach for interpreting genome-wide expression profiles. Proc. Natl.
Acad. Sci. U S A 102, 15545–15550.
Torrezan, G.T., Ferreira, E.N., Nakahata, A.M., Barros, B.D., Castro, M.T.,
Correa, B.R., Krepischi, A.C., Olivieri, E.H., Cunha, I.W., Tabori, U., et al.C(2014). Recurrent somatic mutation in DROSHA induces microRNA profile
changes in Wilms tumour. Nat. Commun. 5, 4039.
Tusher, V., Tibshirani, R., and Chu, G. (2001). Significance analysis of microar-
rays applied to transcriptional responses to ionizing radiation. Proc. Natl.
Acad. Sci. U S A 98, 5116–5121.
Urbach, A., Yermalovich, A., Zhang, J., Spina, C.S., Zhu, H., Perez-Atayde,
A.R., Shukrun, R., Charlton, J., Sebire, N., Mifsud, W., et al. (2014). Lin28 sus-
tains early renal progenitors and induces Wilms tumor. Genes Dev. 28,
971–982.
Viswanathan, S.R., Powers, J.T., Einhorn, W., Hoshida, Y., Ng, T.L., Toffanin,
S., O’Sullivan, M., Lu, J., Phillips, L.A., Lockhart, V.L., et al. (2009). Lin28 pro-
motes transformation and is associated with advanced human malignancies.
Nat. Genet. 41, 843–848.
Wegert, J., Ishaque, N., Vardapour, R., Geo¨rg, C., Gu, Z., Bieg, M., Ziegler, B.,
Bausenwein, S., Nourkami, N., Ludwig, N., et al. (2015). Mutations in the SIX1/
2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex
underlie high-risk blastemal type Wilms tumors. Cancer Cell 27, this issue,
298–311.
Winter, J., Jung, S., Keller, S., Gregory, R.I., and Diederichs, S. (2009). Many
roads to maturity: microRNA biogenesis pathways and their regulation. Nat.
Cell Biol. 11, 228–234.
Wu, M.K., Sabbaghian, N., Xu, B., Addidou-Kalucki, S., Bernard, C., Zou, D.,
Reeve, A.E., Eccles, M.R., Cole, C., Choong, C.S., et al. (2013). Biallelic
DICER1 mutations occur in Wilms tumours. J. Pathol. 230, 154–164.
Xu, P.X., Zheng,W., Huang, L., Maire, P., Laclef, C., and Silvius, D. (2003). Six1
is required for the early organogenesis of mammalian kidney. Development
130, 3085–3094.ancer Cell 27, 286–297, February 9, 2015 ª2015 Elsevier Inc. 297
